DE60325502D1 - Kombination aus docetaxel und einem cdk-hemmer - Google Patents

Kombination aus docetaxel und einem cdk-hemmer

Info

Publication number
DE60325502D1
DE60325502D1 DE60325502T DE60325502T DE60325502D1 DE 60325502 D1 DE60325502 D1 DE 60325502D1 DE 60325502 T DE60325502 T DE 60325502T DE 60325502 T DE60325502 T DE 60325502T DE 60325502 D1 DE60325502 D1 DE 60325502D1
Authority
DE
Germany
Prior art keywords
docetaxel
combination
cdk
hemmer
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325502T
Other languages
English (en)
Inventor
Athos Giannella-Borradori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0225872.1A external-priority patent/GB0225872D0/en
Priority claimed from GB0318813A external-priority patent/GB0318813D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of DE60325502D1 publication Critical patent/DE60325502D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE60325502T 2002-11-06 2003-11-05 Kombination aus docetaxel und einem cdk-hemmer Expired - Lifetime DE60325502D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0225872.1A GB0225872D0 (en) 2002-11-06 2002-11-06 Combination
GB0318813A GB0318813D0 (en) 2003-08-11 2003-08-11 Combination
PCT/GB2003/004780 WO2004041268A1 (en) 2002-11-06 2003-11-05 Combination comprising docetaxel and a cdk inhibitor

Publications (1)

Publication Number Publication Date
DE60325502D1 true DE60325502D1 (de) 2009-02-05

Family

ID=32313983

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325502T Expired - Lifetime DE60325502D1 (de) 2002-11-06 2003-11-05 Kombination aus docetaxel und einem cdk-hemmer

Country Status (11)

Country Link
US (1) US20050277656A1 (de)
EP (1) EP1558242B1 (de)
JP (1) JP4764165B2 (de)
AT (1) ATE418333T1 (de)
AU (1) AU2003276467A1 (de)
BR (1) BR0316010A (de)
CA (1) CA2502973A1 (de)
DE (1) DE60325502D1 (de)
ES (1) ES2318202T3 (de)
MX (1) MXPA05004917A (de)
WO (1) WO2004041268A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
WO2005044275A1 (en) * 2003-11-06 2005-05-19 Cyclacel Limited Use
BRPI0707580A2 (pt) * 2006-02-10 2011-05-10 Nerviano Medical Sciences Srl combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico
DK2596801T3 (en) * 2006-10-06 2018-08-13 Bavarian Nordic As RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
WO2009006555A2 (en) * 2007-07-02 2009-01-08 Yu, Ming Methods, composition, targets for combinational cancer treatments
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
WO2002046182A1 (en) * 2000-12-08 2002-06-13 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors
US20020182204A1 (en) * 2001-03-23 2002-12-05 Marie-Christine Bissery Combination of a taxane and a cyclin-dependent kinase
WO2003039536A1 (en) * 2001-11-07 2003-05-15 Yale University Enhancement of taxane-based chemotherapy by a cdk1 antagonist
JP2005526086A (ja) * 2002-03-15 2005-09-02 サイクラセル・リミテッド 癌の治療用のｃｄｋ阻害剤と５−ｆｕの組合せ
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
AU2003276463A1 (en) * 2002-11-06 2004-06-07 Cyclacel Limited Combination comprising a cdk inhibitor and cisplatin
JP2006508184A (ja) * 2002-11-06 2006-03-09 サイクラセル・リミテッド Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物

Also Published As

Publication number Publication date
ES2318202T3 (es) 2009-05-01
EP1558242B1 (de) 2008-12-24
JP4764165B2 (ja) 2011-08-31
ATE418333T1 (de) 2009-01-15
JP2006508186A (ja) 2006-03-09
EP1558242A1 (de) 2005-08-03
CA2502973A1 (en) 2004-05-21
MXPA05004917A (es) 2005-08-18
BR0316010A (pt) 2005-09-13
WO2004041268A1 (en) 2004-05-21
AU2003276467A1 (en) 2004-06-07
US20050277656A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
MXPA05004919A (es) Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE504303T1 (de) Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE60325502D1 (de) Kombination aus docetaxel und einem cdk-hemmer
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
BRPI0511475A (pt) combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MXPA05004920A (es) Combinacion que comprende un inhibidor cdk y cisplatin.
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
BR0316029A (pt) Combinação
MXPA04009396A (es) Combinacion que comprende un inhibidor cdk y doxorubicina.
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition